reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
A study in 2005 reported that, among a sample of undergraduate students, the most frequently cited sources for knowledge about the clitoris were school and friends, and that this was associated with the least tested knowledge. Knowledge of the clitoris by self-exploration was the least cited, but "respondents correctly answered, on average, three of the five clitoral knowledge measures". The authors stated that "[k]nowledge correlated significantly with the frequency of women's orgasm in masturbation but not partnered sex" and that their "results are discussed in light of gender inequality and a social construction of sexuality, endorsed by both men and women, that privileges men's sexual pleasure over women's, such that orgasm for women is pleasing but ultimately incidental". They concluded that part of the solution to remedying "this problem" requires that males and females are taught more about the clitoris than is currently practiced. The humanitarian group Clitoraid launched the first annual International Clitoris Awareness Week, from 6 to 12 May in 2015. Clitoraid spokesperson Nadine Gary stated that the group's mission is to raise public awareness about the clitoris because it has "been ignored, vilified, made taboo, and considered sinful and shameful for centuries". (See also Vulva activism) Odile Fillod created a 3D printable, open source, full-size model of the clitoris, for use in a set of anti-sexist videos she had been commissioned to produce.
== Medical devices == A variety of medical devices are in use or under consideration for treatment of depression including devices that offer electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and cranial electrotherapy stimulation. The use of such devices in the United States requires approval by the U.S. Food and Drug Administration (FDA) after field trials. In 2010 an FDA advisory panel considered the question of how such field trials should be managed. Factors considered were whether drugs had been effective, how many different drugs had been tried, and what tolerance for suicides should be in field trials.
Cardiac PET can be used to assess myocardial blood flow, and can also be used to diagnose heart conditions such as coronary artery disease, cardiac amyloidosis, and cardiac sarcoidosis. It has also been used to test the efficacy of novel anti-atherosclerosis therapies. Commonly used radiotracers in cardiac PET are Rubidium-82, Nitrogen-13 ammonia and Oxygen-15 water. Compared to cardiac SPECT, another commonly used nuclear medicine imaging modality in cardiology, PET offers superior image quality and improved diagnostic accuracy for coronary artery disease. Despite the technical advantages of PET over SPECT, there is some debate over which modality is more cost effective: SPECT scanners are generally cheaper, and have a wider install base, though some studies have found that using PET results in less downstream healthcare utilisation.
Sources: en.wikipedia.org
Amat-Mamu was a nadītu, a priestess to the god Shamash. She was the daughter of Sin-ilum (also transcribed as Sîn-ilum or Sin-ili). Sin-ilum was the son of Sin-tajjār, who in turn was the son of Akšāja. Amat-Mamu had a cousin, an aunt, and a great aunt who were all nadītus as well. Nadītus were sometimes allowed to choose their own heirs, including potential heirs outside of their own families. Such an option was allowed to the nadītu Belessunu, daughter of Mannium, as part of the terms of her own adoption as the heir of her aunt Naramtum, and Belessunu adopted Amat-Mamu as her heir. Amat-Mamu inherited four fields totaling 46 acres: a five-acre field and a 20 acre field in the Pzur-Ilaba district, a nine-acre field in the Akbarum district, and a 12 acre field in the Pahuşu district. She also inherited two plots of land: one and one-third sar of partially developed land in the cloister and six sar of undeveloped land of Sippar-rabum. Amat-Mamu inherited three slaves from Belessunu: Ana-pani-Šamaš-nadi, Sin-mašmaš, and Sin-mašmaš's brother. Also inherited were a house, two copper pots, and two axes. Amat-Mamu was given the deeds, or "mother tablets", entitling her to Belessunu's property. Per the terms of the agreement, Amat-Mamu was required to pay Belessunu's debts and provide for her while she lived. The debt totaled two-thirds mina, six shekels of silver. To provide for Belessunu, Amat-Mamu was required to provide Belessunu with six gurs of grain, 12 minas of wool, 24 liters of oil, six feasts, 20 liters of flour, and two pieces of meat each year.
=== Dextran microsphere applications === Dextran-based microspheres can encapsulate a variety of drugs and provide therapeutic delivery in the treatment of diseases such as cancer, colonic diseases, bone diseases, and cardiovascular diseases.
=== Nana Mary === Nana Mary is played by Shelley Winters. Nana Mary is Beverly's mother and Roseanne and Jackie's grandmother, and first appears at a family barbecue in season three. She has another daughter named Sonya. She makes several appearances from season three onward, mostly during family occasions. She is a brash but caring, outspoken, lovable retiree who gambles with her grandchildren. Unlike Bev, she is popular with the family. She also disagrees with Bev in certain situations, such as siding with Jackie when Bev urges her to marry Fred, and revealing that she had two abortions, upsetting Bev. She outsmarts Bev and torments her, much to the amusement of Roseanne and Jackie, who usually endure the same treatment from Bev. Her character is often a comic relief for the family, as well as offering a balance between Roseanne and Jackie's relationship with their mother, and Bev's relationship with Nana Mary. She was promiscuous in her youth and claims that as a globe-trotting free spirit she knew Pablo Picasso, Louis Armstrong, Ernest Hemingway, Fidel Castro, and Meyer Lansky, among others. Mary had Bev with another man before marrying her deceased husband, Marvin. She tells Bev she was very young when she gave birth, admits to not knowing who the father is, and avoided the subject until Bev demanded to finally know. Mary is a fan of a local radio call-in show that revolves around sex: "If I don't call, they worry," she claims.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Dry powder is kept frozen, commonly at minus twenty degrees Celsius or below. It should be protected from light and moisture. Dissolved material is less stable and is generally used soon after preparation.